No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
848 |
4. Check minimum number of eventsNone |
848 |
5. Include endpoints |
879 |
6. Filter based on genotype QC (FinnGen only) |
879 |
Control definitions (FinnGen only)
- Control exclude
- H7_OCUMUSCLE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H49-H52
- Name in latin
- Aliae perturbationes motus binocularis
Similar endpoints
↥List of similar endpoints to
Other disorders of binocular movement
based on the number of shared cases.
Similar with more cases:
- Disorders of ocular muscles, binocular movement, accommodation and refraction
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 6549 | 3902 | 2630 |
| Only index persons | 5992 | 3644 | 2348 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.10 | 0.11 | 0.07 |
| Only index persons | 0.12 | 0.13 | 0.09 |
| Median age at first event (years) | |||
| Whole population | 26.83 | 27.34 | 25.99 |
| Only index persons | 28.28 | 28.58 | 27.82 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 879 | 625 | 254 |
| Unadjusted period prevalence (%) | 0.18 | 0.21 | 0.11 |
| Median age at first event (years) | 36.37 | 32.80 | 45.16 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 747
- Matched controls
- 7471
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H51.1
ICD-10 Finland
Convergence insufficiency and excess
+∞
323.0
449
*
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
117.9
110
*
H53.3
ICD-10 Finland
Other disorders of binocular vision
166.4
97.8
101
7
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
+∞
85.0
80
*
H50.52
ICD-10 Finland
Exophoria
456.1
83.7
82
*
H53.2
ICD-10 Finland
Diplopia
25.1
77.2
110
51
H51.9
ICD-10 Finland
Disorder of binocular movement, unspecified
744.7
70.3
68
*
H50.31
ICD-10 Finland
Intermittent exotropia
567.1
54.2
53
*
H50.1
ICD-10 Finland
Divergent concomitant strabismus
+∞
45.3
43
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.5
43.4
139
296
AA1AD
NOMESCO Finland
CT of head and brain
3.5
38.1
208
733
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.2
35.8
119
261
R51.80
ICD-10 Finland
Headache
3.4
33.4
193
699
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.4
31.3
171
592
TAB00
NOMESCO Finland
Lumbar puncture
7.2
30.6
77
118
H51.0
ICD-10 Finland
Palsy of conjugate gaze
+∞
27.2
26
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.3
26.9
108
285
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
+∞
26.2
25
*
G35
ICD-10 Finland
Multiple sclerosis
10.8
24.9
48
47
N03AX12
ATC
gabapentin; oral
3.1
24.3
147
539
CEC00
NOMESCO Finland
Recession of extraocular muscle
+∞
24.1
23
*
H50.2
ICD-10 Finland
Vertical strabismus
129.1
23.7
25
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.0
23.2
99
275
H50.0
ICD-10 Finland
Convergent concomitant strabismus
+∞
23.0
22
*
3788X
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Other disorders of binocular eye movements
+∞
23.0
22
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
13.4
21.3
37
29
109
Kela drug reimbursment
Multiple sclerosis
12.1
20.9
38
33
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.9
20.6
140
551
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.1
20.6
84
224
H53.1
ICD-10 Finland
Subjective visual disturbances
4.4
20.2
77
192
XA800
NOMESCO Finland
Neuropsychological investigation
5.1
20.2
65
136
Z01.8
ICD-10 Finland
Other specified special examinations
2.5
19.8
185
873
XCK00
NOMESCO Finland
Perimetry
4.6
19.4
69
161
N03AG01
ATC
valproic acid; systemic, rectal
3.9
18.2
79
222
H52.0
ICD-10 Finland
Hypermetropia
33.8
18.0
23
7
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
2.5
18.0
159
726
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
27.5
17.9
24
9
L03AX13
ATC
glatiramer acetate; parenteral
23.5
17.8
25
11
WX704
NOMESCO Finland
Intubation
3.7
17.5
80
235
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
8.0
17.3
39
51
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
6.3
17.2
46
77
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
+∞
16.7
16
*
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.8
16.7
72
202
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
11.1
16.6
31
29
H50.30
ICD-10 Finland
Intermittent esotropy
173.7
16.6
17
*
H52.5
ICD-10 Finland
Disorders of accommodation
173.7
16.6
17
*
H52.1
ICD-10 Finland
Myopia
9.1
16.3
34
39
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
16.3
164
797
WX725
NOMESCO Finland
Noninvasive ventilation
4.5
15.9
57
134
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
5.1
15.8
50
103
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
+∞
15.7
15
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.0
15.1
90
322
M03BX01
ATC
baclofen; systemic
8.5
14.9
32
39
R42
ICD-10 Finland
Dizziness and giddiness
2.3
14.8
155
765
SPAT1028
SPAT
Ultrasound examination of paranasal sinuses
3.4
14.1
70
220
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
2.9
14.0
90
340
SAA03
NOMESCO Finland
Extended examination of mouth
1.8
13.7
326
2220
37301
ICD-8 Finland
Strabismus, Concomitans divergens
+∞
13.6
13
*
WX720
NOMESCO Finland
Own respiration
4.8
13.5
45
99
UKC02
NOMESCO Finland
Cystoscopy
2.7
13.2
98
402
A02BC03
ATC
lansoprazole; oral
2.0
12.9
194
1114
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
12.6
267
1733
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
2.6
12.6
95
395
CEC30
NOMESCO Finland
Resection of extraocular muscle
+∞
12.5
12
*
H50.8
ICD-10 Finland
Other specified strabismus
+∞
12.5
12
*
H50.9
ICD-10 Finland
Strabismus, unspecified
+∞
12.5
12
*
L28
ICPC
Limited function/disability (L)
2.4
12.4
108
484
SPAT1301
SPAT
No procedures
1.9
12.4
241
1515
R20.2
ICD-10 Finland
Paraesthesia of skin
3.2
12.4
67
225
N06AX21
ATC
duloxetine; oral
2.6
12.3
96
405
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.1
12.3
70
243
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.8
12.3
257
1655
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.5
12.2
57
172
N03AX16
ATC
pregabalin; oral
2.1
12.1
160
867
SPAT1263
SPAT
Sampling
1.8
11.9
334
2358
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
12.8
11.7
20
16
N86
ICPC
Multiple sclerosis
30.6
11.7
15
5
XKD06
NOMESCO Finland
Physiologic investigation of micturition
6.1
11.3
30
51
SHB00
NOMESCO Finland
Prepation and fitting of bite rail to mouth
2.3
10.8
105
496
SPAT1324
SPAT
Screening procedure
1.9
10.8
168
969
L03AB07
ATC
interferon beta-1a; parenteral
11.4
10.6
19
17
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
9.4
10.6
21
23
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
10.2
10.6
20
20
H50.51
ICD-10 Finland
Esophoria
111.5
10.4
11
*
H49.1
ICD-10 Finland
Fourth [trochlear] nerve palsy
+∞
10.4
10
*
KMAK
NOMESCO Finland
NA
1.7
10.3
405
3106
R03AC02
ATC
salbutamol; inhalant
1.7
10.3
393
2991
N07AA02
ATC
pyridostigmine; systemic
23.7
10.3
14
6
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.3
10.2
96
447
SHA02
NOMESCO Finland
Correction of physiology of bite - basic therapy visit
2.6
10.2
72
289
XKC03
NOMESCO Finland
Water cystometry
4.7
10.1
33
72
K07.60
ICD-10 Finland
Snapping jaw
3.0
10.0
57
199
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
5.3
9.9
29
56
N03AE01
ATC
clonazepam; systemic
3.3
9.9
50
161
WYA05
NOMESCO Finland
Emergency visit or other similar visit involving procedures
1.6
9.9
366
2754
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
26.4
9.8
13
5
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
2.3
9.8
91
420
WX702
NOMESCO Finland
Supraglottic ventilation device
3.1
9.7
53
180
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.8
9.4
39
107
-1
NOMESCO Finland
NA
1.7
9.4
280
1974
C07AA05
ATC
propranolol; systemic
1.9
9.4
156
919
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.7
9.4
277
1948
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
3.3
9.4
47
151
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
8.8
9.3
19
22
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.4
9.3
83
377
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.3
9.1
45
143
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.4
9.1
79
353
G44.2
ICD-10 Finland
Tension-type headache
2.1
9.0
112
590
SPAT1260
SPAT
Consultation of another employee
1.9
8.9
132
743
N01
ICPC
Headache
2.0
8.9
117
627
N06AA09
ATC
amitriptyline; systemic
2.5
8.8
69
292
G51.0
ICD-10 Finland
Bell palsy
4.8
8.8
28
60
J45.9
ICD-10 Finland
Asthma, unspecified
2.0
8.8
122
671
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.4
8.8
74
324
N03AX14
ATC
levetiracetam; systemic
4.4
8.7
30
70
A28
ICPC
Limited function/disability NOS
2.3
8.6
79
363
R03BA05
ATC
fluticasone; inhalant
1.9
8.5
142
832
M54.4
ICD-10 Finland
Lumbago with sciatica
2.0
8.5
112
602
2AB04
NOMESCO Finland
NA
27.9
8.5
11
*
N29
ICPC
Neurological sympt/complt other
6.8
8.4
20
30
N99
ICPC
Neurological disease other
12.9
8.4
14
11
R03DC03
ATC
montelukast; oral
2.0
8.4
119
660
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.8
8.4
177
1123
CEC90
NOMESCO Finland
Total transposition of extraocular muscle or muscles
+∞
8.3
8
*
N03AX09
ATC
lamotrigine; oral
2.8
8.3
52
193
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.0
8.3
109
587
N02AX02
ATC
tramadol; systemic, rectal
1.6
8.2
246
1725
SPAT1231
SPAT
Assessment of adjustments needed in living environment
7.7
8.2
18
24
G43.9
ICD-10 Finland
Migraine, unspecified
2.5
8.1
65
279
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
4.9
8.1
25
52
N05BA01
ATC
diazepam; systemic, rectal
2.1
8.1
91
458
G70.0
ICD-10 Finland
Myasthenia gravis
33.7
8.1
10
*
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
17.4
8.1
12
7
R96
ICPC
Asthma
2.4
8.1
65
281
N03AF02
ATC
oxcarbazepine; oral
3.7
8.0
33
91
N03AF01
ATC
carbamazepine; oral, rectal
3.2
8.0
40
129
F83
ICD-10 Finland
Mixed specific developmental disorders
7.3
8.0
18
25
N06AX11
ATC
mirtazapine; oral
1.6
7.9
218
1493
H04.10
ICD-10 Finland
Dry eye syndrome
2.3
7.9
72
332
N03AX11
ATC
topiramate; oral
3.9
7.8
31
83
WX400
NOMESCO Finland
Inhalation anesthesy
2.8
7.8
47
173
B80
ICPC
Iron deficiency anaemia
5.4
7.7
22
42
F45.8
ICD-10 Finland
Other somatoform disorders
2.3
7.7
70
319
R53
ICD-10 Finland
Malaise and fatigue
1.8
7.7
139
836
M25.5
ICD-10 Finland
Pain in joint
1.7
7.6
202
1366
R1250
NOMESCO Finland
Evaluation of functional capability
5.0
7.6
23
47
R13
ICD-10 Finland
Dysphagia
2.9
7.6
44
156
SPAT1097
SPAT
Recording of ECG
2.1
7.6
84
421
XLD10
NOMESCO Finland
Gynaecological examination
18.6
7.6
11
6
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
3.0
7.6
43
149
S06.0
ICD-10 Finland
Concussion
2.2
7.6
81
399
A06AC01
ATC
ispaghula (psylla seeds); oral
1.8
7.6
143
875
M01AE03
ATC
ketoprofen; systemic, rectal
1.6
7.6
225
1566
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.1
7.5
81
402
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.4
7.4
61
266
G40.9
ICD-10 Finland
Epilepsy, unspecified
3.7
7.4
31
87
H52.3
ICD-10 Finland
Anisometropia and aniseikonia
80.8
7.4
8
*
F43.1
ICD-10 Finland
Post-traumatic stress disorder
3.2
7.3
36
115
A06AD11
ATC
lactulose; oral
2.2
7.3
77
375
N28
ICPC
Limited function/disability (N)
6.9
7.3
17
25
H53.0
ICD-10 Finland
Amblyopia ex anopsia
9.5
7.3
14
15
CEC60
NOMESCO Finland
Transposition of extraocular muscle with adjustable suture
+∞
7.3
7
*
3503
FHL
Single muscle retroposition
+∞
7.3
7
*
R07.4
ICD-10 Finland
Chest pain, unspecified
1.7
7.3
151
947
R02
ICPC
Shortness of breath/dyspnoea
2.1
7.2
77
380
R52.2
ICD-10 Finland
Other chronic pain
3.8
7.2
29
79
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
3.9
7.2
28
74
N05BA06
ATC
lorazepam; systemic, sublingual
3.2
7.1
35
112
183
Kela drug reimbursment
Lamotrigin and topiramate
6.1
7.1
18
30
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
2.6
7.0
48
190
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
5.5
6.9
19
35
SXA05
NOMESCO Finland
NA
6.8
6.8
16
24
A03FA02
ATC
cisapride; oral, rectal
2.6
6.8
47
185
A02BC01
ATC
omeprazole; systemic
1.7
6.7
168
1113
A02BC05
ATC
esomeprazole; systemic
1.5
6.7
253
1858
J01DA01
ATC
[U] cefalexin; systemic
1.5
6.7
424
3493
A04
ICPC
Weakness/tiredness general
1.9
6.7
100
562
G46.3*I67.9
ICD-10 Finland
Brain stem stroke syndrome (I60-I67+)
22.7
6.7
9
*
G44.8
ICD-10 Finland
Other specified headache syndromes
6.5
6.7
16
25
M35.7
ICD-10 Finland
Hypermobility syndrome
4.9
6.6
20
42
R56.8
ICD-10 Finland
Other and unspecified convulsions
2.6
6.5
44
174
H46
ICD-10 Finland
Optic neuritis
6.3
6.5
16
26
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
6.3
6.5
16
26
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
1.6
6.5
174
1175
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
70.4
6.4
7
*
CE2W4
NOMESCO Finland
Eye movement mapping
70.4
6.4
7
*
N02CC03
ATC
zolmitriptan; nasal, oral
2.4
6.4
51
218
G91.0
ICD-10 Finland
Communicating hydrocephalus
14.5
6.4
10
7
M50.3
ICD-10 Finland
Other cervical disc degeneration
4.5
6.4
21
48
A02BA02
ATC
ranitidine; systemic
1.8
6.4
113
673
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
1.7
6.3
127
787
164
Kela drug reimbursment
Fingolimod
11.1
6.3
11
10
H57.1
ICD-10 Finland
Ocular pain
3.1
6.3
32
106
H52.2
ICD-10 Finland
Astigmatism
9.4
6.3
12
13
J45.0
ICD-10 Finland
Predominantly allergic asthma
2.1
6.3
72
366
WX408
NOMESCO Finland
General anesthesy, balanced
1.6
6.3
171
1158
RS142
NOMESCO Finland
NA
18.2
6.3
9
5
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
2.3
6.3
56
256
R06.0
ICD-10 Finland
Dyspnoea
1.7
6.3
145
940
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
4.8
6.3
19
40
3789X
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Unspecified disorder of eye movements
+∞
6.3
6
*
G23.1
ICD-10 Finland
Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
+∞
6.3
6
*
0148
NOMESCO Finland
NA
+∞
6.3
6
*
F95
ICPC
Strabismus
+∞
6.3
6
*
108
Kela drug reimbursment
Myasthenia gravis
26.9
6.2
8
*
G80.1
ICD-10 Finland
Spastic diplegic cerebral palsy
26.9
6.2
8
*
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
2.1
6.2
65
319
R44
ICPC
Respiratory, Preventive immunization/medic
5.8
6.2
16
28
AA5BD
NOMESCO Finland
CT of cerebral ischaemia
5.8
6.2
16
28
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
2.2
6.2
58
272
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
4.3
6.2
21
50
A01
ICPC
Pain general/multiple sites
2.3
6.1
55
252
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
8.7
6.1
12
14
M03BA52
ATC
carisoprodol, combinations excl. psycholeptics; oral
3.5
6.1
26
76
JN3AD
NOMESCO Finland
Abdominal CT examination
2.5
6.1
46
193
D21
ICPC
Swallowing problem
6.8
6.1
14
21
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
10.1
6.0
11
11
XKD00
NOMESCO Finland
Uroflowmetry
2.0
6.0
73
382
N62
ICD-10 Finland
Hypertrophy of breast
2.9
6.0
35
126
N05CF01
ATC
zopiclone; oral
1.6
6.0
175
1201
N04BB01
ATC
amantadine; oral
5.6
6.0
16
29
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
82
162
5.48
40.10
1.5
1.6
1966.0
807.9
e6/l
0.25
68
125
82
162
5.48
40.10
1.5
1.5
174.8
16.2
e6/l
0.51
65
120
81
160
5.47
39.61
1.2
1.5
3.5
3.7
mmol/l
1.12
75
149
51
77
6.97
32.60
1.1
1.1
—
—
—
0
0
322
1699
2.41
32.38
2.4
2.0
215.9
186.2
u/l
0.27
307
1599
51
80
6.71
31.45
1.1
1.1
—
—
—
0
0
47
70
7.04
30.40
1.2
1.2
36.2
40.6
mg/l
0.22
38
57
45
65
7.24
29.92
1.1
1.1
218.7
239.6
mg/l
0.26
40
56
45
72
6.53
27.21
1.1
1.1
—
—
—
0
0
42
64
6.84
26.58
1.1
1.1
—
—
—
0
0
35
44
8.24
26.16
1.2
1.0
0.4
0.1
nmol/l
—
12
7
38
54
7.31
25.61
1.9
1.3
—
—
—
0
0
195
905
2.48
25.19
2.2
2.3
28.5
29.7
s
2.80
183
874
36
54
6.91
23.10
1.1
1.1
1.0
1.1
u/l
0.42
16
25
24
22
11.19
22.52
2.1
1.4
—
—
—
0
0
394
2524
2.02
22.30
5.2
4.5
36.6
36.5
g/l
0.12
372
2358
532
3801
2.01
21.89
6.4
4.6
6.3
6.5
mmol/l
1.22
466
3432
127
541
2.58
19.34
2.5
2.7
10.3
10.1
g/l
0.14
114
500
430
2979
1.87
18.08
8.6
6.4
1.2
1.2
mmol/l
0.20
372
2533
314
2017
1.87
16.36
2.9
2.4
59.7
56.1
u/l
0.22
294
1871
201
1111
2.05
16.32
3.9
3.4
81.3
436.5
ng/l
2.53
122
721
387
2674
1.80
15.73
7.7
5.9
1.2
1.2
mmol/l
1.07
362
2454
93
378
2.63
15.49
3.0
3.0
142.0
152.3
ng/l
0.09
87
333
174
943
2.05
14.78
1.7
1.7
1098.2
1183.8
nmol/l
0.63
140
727
131
637
2.24
14.69
2.1
1.7
—
—
—
0
0
131
642
2.22
14.40
2.1
1.8
—
—
—
0
0
594
4740
1.78
13.95
5.8
3.9
44.7
1145.5
e6/l
—
6
54
119
577
2.23
13.39
7.2
8.9
1.1
1.0
mmol/l
0.04
87
453
138
719
2.09
12.92
5.2
6.1
1.0
1.1
mmol/l
0.68
131
668
117
576
2.19
12.66
7.4
8.9
4.9
5.1
kpa
1.71
108
548
117
576
2.19
12.66
7.3
8.9
13.1
12.9
kpa
0.11
109
550
526
4117
1.69
12.61
9.7
8.3
4.0
4.0
e9/l
0.06
483
3606
338
2355
1.71
12.59
3.7
3.1
26.7
29.7
u/l
1.42
319
2241
75
308
2.57
12.21
6.8
8.7
24.0
24.4
mmol/l
0.55
69
287
15
17
8.96
12.03
5.4
2.5
—
—
—
0
0
99
471
2.24
11.63
7.8
9.1
122.0
121.8
g/l
0.02
93
455
241
1563
1.75
11.43
4.2
3.3
1.0
1.0
kg/l
0.31
42
223
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
21
39
5.49
10.91
1.3
1.1
—
—
—
0
0
430
3274
1.61
10.83
5.3
5.7
10.1
10.8
umol/l
0.90
407
3080
616
5127
1.67
10.77
4.2
3.7
10.2
10.3
mm/h
0.07
593
4766
789
7078
2.12
10.56
18.3
12.1
139.8
139.6
mmol/l
1.81
778
6874
157
926
1.85
10.13
2.1
1.8
—
—
—
0
0
789
7104
2.08
10.04
18.3
12.2
3.9
3.9
mmol/l
0.39
777
6884
18
32
5.72
9.78
1.2
1.1
—
—
—
0
0
41
138
3.07
9.69
1.2
1.1
—
—
—
0
0
326
2371
1.60
9.63
1.9
1.8
94.6
95.5
pmol/l
0.12
161
1268
602
5048
1.61
9.55
7.2
6.6
77.3
77.2
u/l
0.02
571
4736
155
934
1.80
9.28
3.5
3.6
0.8
0.8
mmol/l
0.25
145
884
204
1334
1.69
9.14
1.5
1.4
21.3
20.6
nmol/l
0.29
187
1163
104
554
1.99
9.07
7.1
4.6
2.0
1.8
mmol/l
0.33
90
441
120
683
1.88
8.60
2.3
2.0
378.7
378.9
nmol/l
0.00
108
632
242
1682
1.61
8.44
2.4
2.1
2.4
2.8
mg/l
2.38
216
1443
65
297
2.28
8.41
1.3
2.1
35.4
40.2
u/l
1.32
60
268
663
5783
1.60
8.03
5.0
4.0
14.6
14.5
pmol/l
0.62
628
5332
446
3585
1.50
7.85
4.1
3.2
0.0
0.0
estimate
0.00
70
704
15
28
5.43
7.75
1.3
1.1
—
—
—
0
0
87
478
1.91
6.93
7.9
4.1
4.8
4.7
kpa
0.05
87
461
78
415
1.97
6.83
2.1
1.7
—
—
—
0
0
179
1218
1.59
6.66
1.7
1.6
439.1
24643620.7
pmol/l
1.32
156
1051
144
929
1.66
6.64
2.3
2.2
13.2
14.0
umol/l
0.80
137
852
23
69
3.40
6.59
2.9
2.8
13.2
12.2
%
0.19
14
43
75
399
1.96
6.58
2.5
2.4
67.2
67.0
g/l
0.07
69
366
578
4987
1.46
6.52
3.4
2.9
35.7
38.3
u/l
0.45
549
4746
438
3600
1.43
6.36
5.8
4.4
0.0
0.0
estimate
0.50
68
717
713
6436
1.57
6.34
19.8
13.7
13.4
13.4
%
0.02
707
6311
742
6761
1.63
6.33
5.8
4.6
1.7
2.0
mu/l
0.98
709
6330
130
844
1.63
5.83
2.3
2.2
2.5
2.4
g/l
0.75
125
773
437
3632
1.40
5.74
4.2
3.2
0.0
0.0
estimate
0.80
67
691
26
94
2.82
5.50
1.4
1.4
—
—
—
0
0
74
417
1.85
5.48
4.4
4.0
86.6
70.8
ng/l
0.76
67
378
31
126
2.51
5.25
2.5
3.4
26.8
34.3
umol/l
1.08
26
109
256
1964
1.43
5.20
1.4
1.3
0.5
2.0
u/ml
3.97
63
523
20
65
3.13
5.09
2.9
2.8
—
—
—
0
0
431
3640
1.36
4.82
3.4
2.8
92.4
85.1
ug/l
0.28
409
3413
221
1671
1.43
4.82
1.7
1.6
1.4
1.4
mmol/l
0.36
208
1435
116
768
1.59
4.79
2.4
2.3
22.1
23.6
%
0.46
84
662
176
1276
1.47
4.78
1.3
1.3
17.7
30.7
iu/ml
1.87
51
377
77
463
1.73
4.62
1.7
1.6
—
—
—
0
0
19
64
3.01
4.57
1.5
1.4
274.9
381.1
pmol/l
0.89
14
49
262
2057
1.39
4.57
3.2
3.1
2.3
2.4
mmol/l
2.15
243
1858
98
630
1.63
4.57
3.2
2.3
5394.0
4402.3
u/l
0.15
43
275
406
3423
1.35
4.48
5.2
4.0
—
—
—
0
0
776
7273
1.57
4.47
16.7
11.3
19.9
20.2
mg/l
0.09
617
5601
338
2774
1.35
4.45
4.4
3.2
—
—
—
0
0
806
7629
1.68
4.39
10.9
8.7
24.5
25.4
u/l
1.15
787
7388
166
1211
1.46
4.35
1.2
1.3
1.8
10.1
u/ml
5.71
61
496
83
519
1.66
4.32
3.1
3.5
4.6
4.6
pmol/l
0.14
74
467
100
656
1.59
4.30
8.1
5.8
—
—
—
0
0
44
228
1.98
4.23
5.0
3.4
51.0
50.3
%
0.07
44
223
757
7080
1.50
4.15
19.4
12.2
39.4
40.1
%
1.17
531
5661
53
298
1.83
4.01
1.3
1.2
0.2
1.4
u/ml
—
9
22
341
2838
1.33
3.98
2.7
2.3
75.0
73.9
nmol/l
0.30
316
2607
33
159
2.12
3.87
1.8
2.0
—
—
—
0
0
29
133
2.22
3.83
2.3
1.8
13.7
13.1
%
1.01
29
133
8
12
6.72
3.68
1.1
1.1
—
—
—
0
0
9
16
5.67
3.66
1.0
1.1
—
—
—
0
0
11
30
3.70
3.64
2.2
5.0
91.6
139.6
umol/l
—
5
18
10
26
3.88
3.53
1.1
1.0
—
—
—
0
0
277
2274
1.32
3.46
4.2
2.9
—
—
—
0
0
32
160
2.04
3.43
1.6
1.8
2.9
3.2
g/l
1.36
23
130
34
174
1.99
3.43
1.7
1.8
6.9
7.3
g/l
0.50
23
136
602
6513
0.76
3.42
12.4
9.8
90.9
89.9
ml/min/173m2
0.52
487
5187
41
224
1.87
3.42
1.5
1.9
—
—
—
0
0
9
18
5.04
3.37
1.3
1.1
—
—
—
0
0
9
18
5.04
3.37
1.3
1.1
—
—
—
0
0
9
19
4.77
3.24
1.4
1.2
—
—
—
0
0
40
221
1.85
3.24
2.0
2.0
2.2
4.9
iu/l
2.83
18
80
12
38
3.19
3.22
1.2
1.1
1817.2
1635.9
miu/ml
0.16
12
38
33
174
1.93
3.08
1.7
1.8
3.6
3.8
g/l
0.31
21
128
33
174
1.93
3.08
1.7
1.8
—
—
—
0
0
31
161
1.96
3.03
1.7
1.8
10.1
10.4
g/l
0.17
23
143
7
12
5.87
3.02
1.1
1.1
—
—
—
0
0
7
12
5.87
3.02
1.1
1.1
—
—
—
0
0
41
235
1.78
2.97
1.4
1.6
233.3
0.3
iu/ml
—
9
37
59
376
1.61
2.91
1.6
1.5
—
—
—
0
0
211
1709
1.31
2.84
1.6
1.5
—
—
—
0
0
10
31
3.25
2.78
1.0
2.7
338.8
590.0
u/ml
—
10
31
18
78
2.34
2.76
1.2
1.7
—
—
—
0
0
77
529
1.50
2.75
2.0
2.7
0.2
0.2
g/l
0.07
70
502
35
197
1.81
2.71
1.4
2.4
1.4
1.3
g/l
0.27
26
173
78
539
1.49
2.71
1.5
1.3
158.1
230.1
u/ml
0.56
66
501
32
555
0.56
2.70
1.7
1.5
—
—
—
0
0
117
874
1.39
2.68
1.9
1.8
—
—
—
0
0
8
19
4.24
2.68
1.5
1.1
—
—
—
0
0
8
19
4.24
2.68
1.5
1.1
—
—
—
0
0
25
126
2.01
2.67
1.9
1.7
186.5
195.2
pmol/l
0.15
25
116
199
1614
1.30
2.64
2.2
1.9
0.7
1.1
mg/l
2.16
156
1212
135
1037
1.36
2.61
3.1
2.5
0.8
0.9
e6/l
0.25
69
551
6
11
5.48
2.54
1.2
1.2
—
—
—
0
0
10
33
3.05
2.53
2.2
2.9
77.6
112.4
nmol/l
—
10
33
15
63
2.40
2.47
3.8
2.5
1048.3
654.4
e6/l
—
6
23
223
1853
1.27
2.44
2.8
3.2
7.4
8.0
mmol/l
1.01
193
1589
140
1095
1.33
2.41
2.0
1.9
—
—
—
0
0
30
511
0.57
2.39
1.6
1.4
—
—
—
0
0
9
27
3.36
2.39
1.0
1.0
—
—
—
0
0
30
168
1.81
2.39
1.4
1.6
—
—
—
0
0
30
510
0.57
2.38
1.6
1.4
—
—
—
0
0
30
510
0.57
2.38
1.6
1.4
—
—
—
0
0
30
509
0.57
2.36
1.6
1.4
—
—
—
0
0
30
170
1.79
2.31
1.4
1.6
—
—
—
0
0
62
425
1.49
2.27
1.6
1.7
—
—
—
0
0
215
1794
1.26
2.26
3.8
2.8
0.2
0.3
e6/l
1.67
160
1307
5
9
5.58
2.21
1.0
1.0
—
—
—
0
0
22
115
1.94
2.17
1.2
1.3
—
—
—
0
0
22
115
1.94
2.17
1.2
1.3
—
—
—
0
0
48
316
1.55
2.13
1.4
1.4
16.8
9.2
u/l
0.45
43
260
639
6000
1.24
2.11
5.2
4.7
37.6
38.4
mmol/mol
1.41
612
5652
250
2138
1.24
2.11
4.0
3.1
17.0
52.3
ng/l
1.08
145
1198
26
146
1.80
2.08
1.4
1.3
—
—
—
0
0
9
31
2.92
2.07
1.4
1.3
—
—
—
0
0
5
10
5.02
2.07
1.2
1.5
-2.1
2.8
mmol/l
—
5
10
12
50
2.42
2.03
2.3
2.1
—
—
—
0
0
9
32
2.83
2.00
1.4
1.3
—
—
—
0
0
34
211
1.64
1.94
1.3
1.7
—
205.7
—
0
7
13
58
2.26
1.91
1.2
1.2
—
—
—
0
0
24
136
1.79
1.89
4.9
6.7
168.0
438.0
iu/ml
—
5
19
14
65
2.17
1.88
3.4
2.6
106.9
105.3
mmol/l
0.79
14
65
14
65
2.17
1.88
3.4
2.6
4.0
4.0
mmol/l
0.12
14
65
7
22
3.20
1.88
1.3
1.4
—
—
—
0
0
19
100
1.92
1.86
1.7
1.1
—
—
—
0
0
21
115
1.85
1.84
1.2
1.6
—
—
—
0
0
15
74
2.04
1.75
1.5
1.7
—
—
—
0
0
32
202
1.61
1.73
1.9
1.6
37.0
39.8
nmol/l
0.28
32
196
7
24
2.93
1.72
1.3
1.2
195.4
100.4
nmol/l
—
7
15
7
24
2.93
1.72
2.3
2.0
25.1
15.7
umol/l
—
7
24
187
1583
1.23
1.72
3.4
4.0
9.0
9.6
mg/mmol
0.06
108
1020
20
111
1.82
1.69
1.6
1.7
—
1744.0
—
0
5
79
602
1.34
1.66
2.1
2.3
35.5
115.7
u/l
0.48
67
496
31
197
1.59
1.64
2.9
2.0
0.8
3.3
ug/l
1.04
25
178
18
98
1.85
1.62
1.3
1.6
—
—
—
0
0
5
134
0.37
1.62
2.0
1.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
25
151
1.67
1.61
3.6
5.1
0.4
0.3
u/ml
0.59
13
81
690
6593
1.22
1.61
4.3
3.7
5.6
5.7
mmol/l
1.37
644
6114
95
750
1.30
1.57
2.7
2.9
10.2
7.2
umol/l
0.40
77
627
24
380
0.62
1.51
1.8
1.6
2.0
3.1
mg/l
0.72
16
260
19
109
1.76
1.47
2.4
3.7
—
538.1
—
0
9
35
238
1.49
1.41
1.2
1.1
—
—
—
0
0
22
134
1.66
1.40
1.7
1.4
6.2
7.2
mmol/l
1.23
15
91
70
540
1.32
1.39
1.5
1.4
36.3
23.3
iu/l
1.04
60
456
23
143
1.62
1.36
1.1
1.1
—
—
—
0
0
13
68
1.93
1.34
1.6
1.7
—
—
—
0
0
23
144
1.61
1.33
1.1
1.2
1.5
4.8
u/ml
—
8
47
21
129
1.64
1.31
2.8
3.6
57.2
56.8
%
0.05
21
129
6
24
2.51
1.30
4.5
2.2
—
—
—
0
0
6
24
2.51
1.30
2.5
3.0
184.0
195.0
u/l
—
6
24
9
44
2.06
1.27
3.0
1.8
—
—
—
0
0
63
486
1.32
1.27
1.1
1.1
—
—
—
0
0
119
995
1.23
1.25
3.3
2.7
3.8
2.9
e6/l
0.29
54
516
23
147
1.58
1.24
1.1
1.2
5.1
6.0
u/ml
—
10
61
156
1344
1.20
1.21
3.6
2.3
4.5
7.3
e6/l
3.01
142
1166
23
148
1.57
1.21
1.2
1.1
6.4
7.3
u/ml
0.10
13
65
15
86
1.76
1.19
1.1
1.2
—
—
—
0
0
8
38
2.12
1.18
1.1
2.3
30.6
28.9
umol/l
—
8
38
8
38
2.12
1.18
1.7
1.7
—
1224680.0
—
0
5
20
125
1.61
1.18
2.9
3.3
3.8
4.3
e9/l
0.29
20
125
141
1207
1.20
1.18
4.6
4.5
17.5
2.2
ug/l
0.73
131
1083
11
57
1.94
1.17
1.9
1.8
—
—
—
0
0
30
207
1.47
1.16
8.0
5.4
9.6
8.8
kpa
2.47
30
196
83
673
1.26
1.16
1.2
1.2
131.3
160.7
iu/ml
0.27
37
279
26
178
1.47
1.06
1.5
1.4
247.4
326.8
ug/g
1.32
14
102
5
22
2.28
1.03
1.2
2.0
—
—
—
0
0
5
22
2.28
1.03
1.2
2.0
—
—
—
0
0
7
35
2.01
1.00
1.0
1.0
—
—
—
0
0
11
61
1.81
0.98
1.1
1.4
—
—
—
0
0
5
23
2.18
0.98
1.2
1.9
—
—
—
0
0
37
276
1.36
0.97
9.0
5.5
24.7
24.7
mmol/l
0.11
37
265
225
2037
1.14
0.94
1.8
1.7
—
—
—
0
0
49
385
1.29
0.91
2.5
2.2
4.1
6.7
ug/l
1.57
41
342
15
94
1.61
0.91
1.2
1.6
—
—
—
0
0
17
112
1.53
0.85
1.3
1.5
—
—
—
0
0
22
156
1.42
0.79
1.5
1.2
—
—
—
0
0
8
48
1.67
0.79
1.0
1.2
—
—
—
0
0
49
395
1.25
0.77
7.4
4.9
1.2
1.6
mmol/l
0.66
39
287
69
818
0.83
0.76
1.7
1.6
—
—
—
0
0
9
55
1.64
0.73
2.1
1.4
4.9
5.8
mmol/l
—
9
55
14
207
0.67
0.73
1.0
1.3
—
—
—
0
0
18
125
1.45
0.73
2.9
2.5
205.1
119.2
ug/min
0.22
13
73
147
1322
1.13
0.70
3.1
3.2
1492.6
1044.4
ng/l
0.50
119
1098
10
156
0.64
0.68
1.2
1.2
—
—
—
0
0
160
1760
0.89
0.67
2.2
2.2
—
—
—
0
0
5
28
1.79
0.66
1.0
1.0
—
—
—
0
0
5
28
1.79
0.66
1.0
1.0
87.2
89.8
%
—
5
28
74
635
1.18
0.66
1.5
1.4
—
—
—
0
0
27
206
1.32
0.66
1.1
1.2
—
41.2
—
0
10
22
163
1.36
0.64
1.5
1.5
—
—
—
0
0
22
163
1.36
0.64
1.2
1.1
1.9
5.1
u/ml
1.11
13
65
44
360
1.23
0.64
1.8
1.5
—
—
—
0
0
113
1006
1.14
0.63
1.7
1.7
1.3
1.4
%
1.02
108
913
25
190
1.33
0.63
1.4
1.5
0.2
0.4
nmol/l
3.88
17
162
8
49
1.64
0.62
1.9
1.2
—
—
—
0
0
5
30
1.67
0.61
2.4
2.9
—
—
—
0
0
31
245
1.28
0.60
1.3
1.3
—
—
—
0
0
23
175
1.32
0.58
1.7
1.3
250.5
233.9
u/ml
0.11
12
106
108
965
1.14
0.58
4.5
4.0
20.7
21.1
%
0.10
46
430
695
6799
1.11
0.58
4.1
3.7
4.7
4.7
mmol/l
0.38
665
6418
41
337
1.23
0.58
1.4
1.5
—
—
—
0
0
204
1898
1.10
0.54
5.0
3.4
0.0
0.0
estimate
1.34
71
706
6
38
1.58
0.54
1.2
1.2
114.8
500.2
u/l
—
6
33
147
1599
0.90
0.52
2.0
2.1
—
—
—
0
0
9
64
1.41
0.51
1.0
1.1
—
—
—
0
0
9
64
1.41
0.51
1.0
1.1
—
—
—
0
0
9
65
1.39
0.50
1.0
1.1
—
—
—
0
0
9
65
1.39
0.50
1.0
1.1
—
—
—
0
0
9
65
1.39
0.50
1.0
1.1
—
—
—
0
0
44
372
1.19
0.49
1.8
1.9
—
—
—
0
0
36
299
1.21
0.48
1.5
1.7
—
—
—
0
0
23
181
1.28
0.48
1.7
1.3
—
—
—
0
0
23
182
1.27
0.47
5.8
4.4
1.3
1.4
mmol/l
0.21
23
176
19
148
1.29
0.43
1.7
3.2
24.1
24.4
mmol/l
0.15
19
134
5
31
1.62
0.43
1.4
1.7
—
—
—
0
0
5
31
1.62
0.43
1.4
1.7
—
—
—
0
0
5
31
1.62
0.43
1.4
1.7
—
—
—
0
0
5
31
1.62
0.43
1.4
1.7
—
—
—
0
0
15
113
1.33
0.43
1.3
1.8
—
—
—
0
0
63
710
0.88
0.42
2.8
2.9
0.6
0.7
ug/l
1.15
39
441
0
16
0.00
0.41
0.0
4.6
—
1.2
—
0
16
7
101
0.69
0.39
1.0
1.2
—
—
—
0
0
661
6491
1.07
0.39
3.5
3.3
1.3
1.2
mmol/l
0.78
622
6098
10
136
0.73
0.38
2.0
1.4
—
—
—
0
0
10
136
0.73
0.38
2.4
3.1
24.4
27.9
mg/l
—
5
84
53
469
1.14
0.37
3.7
4.2
7.7
32.4
ug/l
0.75
38
376
11
81
1.36
0.36
2.3
1.7
—
—
—
0
0
9
71
1.27
0.36
1.0
1.1
—
—
—
0
0
6
42
1.43
0.35
1.0
1.8
—
—
—
0
0
36
311
1.16
0.34
1.8
1.6
—
—
—
0
0
6
44
1.37
0.34
2.3
3.5
—
—
—
0
0
20
165
1.22
0.31
1.5
1.5
118.6
111.9
u/ml
—
9
31
17
138
1.24
0.30
1.2
1.1
0.0
0.4
u/ml
—
9
39
64
701
0.91
0.29
4.6
3.7
32.9
31.8
%
0.40
49
499
7
57
1.23
0.29
1.3
1.6
—
—
—
0
0
7
57
1.23
0.29
1.3
1.6
—
—
—
0
0
7
57
1.23
0.29
1.3
1.6
—
—
—
0
0
686
6770
1.06
0.29
4.0
3.6
1.5
1.5
mmol/l
0.62
651
6364
19
227
0.83
0.28
1.5
1.6
—
—
—
0
0
51
461
1.11
0.27
2.7
1.7
—
—
—
0
0
8
65
1.23
0.27
1.0
1.2
—
—
—
0
0
8
66
1.21
0.26
1.0
1.3
—
—
—
0
0
47
518
0.90
0.25
1.3
1.4
—
—
—
0
0
9
75
1.20
0.25
1.0
1.7
—
—
—
0
0
19
161
1.18
0.24
2.7
2.6
—
—
—
0
0
6
82
0.73
0.24
1.0
1.6
—
—
—
0
0
6
84
0.71
0.24
2.8
3.6
32.6
3359.7
u/ml
—
6
78
52
476
1.10
0.23
2.6
2.4
65.1
72.9
ml/min/173m2
0.89
25
178
18
211
0.85
0.23
1.6
1.7
—
—
—
0
0
5
39
1.28
0.23
3.0
2.5
61.8
47.9
umol/l
—
5
32
597
5888
1.04
0.22
4.0
3.7
—
—
—
0
0
108
1023
1.06
0.22
2.7
2.5
2.4
2.4
mmol/l
0.11
98
889
5
41
1.22
0.22
1.2
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.5
—
1.0
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
162
1560
1.05
0.19
2.5
2.5
303.4
5000.2
umol/l
4.71
137
1379
37
405
0.91
0.19
1.5
1.3
208.3
250.4
miu/ml
0.32
15
208
6
53
1.13
0.18
1.0
1.4
—
—
—
0
0
21
238
0.88
0.18
1.4
1.2
—
—
—
0
0
696
6902
1.04
0.17
4.5
4.0
2.8
2.8
mmol/l
0.42
661
6463
9
82
1.10
0.15
1.2
2.3
—
—
—
0
0
63
598
1.06
0.13
20.3
16.8
1.2
1.3
inr
—
8
90
16
142
1.13
0.12
1.1
1.2
—
—
—
0
0
58
609
0.95
0.12
4.0
2.9
—
—
—
0
0
12
105
1.14
0.11
1.4
1.5
—
—
—
0
0
21
229
0.91
0.11
1.5
1.9
—
—
—
0
0
13
115
1.13
0.10
1.6
1.8
—
—
—
0
0
160
1636
0.97
0.10
2.4
2.0
—
—
—
0
0
22
237
0.93
0.09
1.4
1.2
0.3
2.5
u/ml
2.22
15
108
94
967
0.97
0.08
1.7
1.5
—
—
—
0
0
12
107
1.12
0.08
1.3
1.2
—
—
—
0
0
10
88
1.14
0.08
1.4
1.4
20.8
34.5
nmol/l
—
10
78
7
82
0.85
0.07
2.0
1.4
—
—
—
0
0
32
304
1.05
0.07
4.2
2.3
0.1
0.1
e6/l
0.74
32
292
13
140
0.93
0.04
1.0
1.1
2.0
2.0
u/ml
—
8
67
21
221
0.95
0.04
1.3
1.2
—
—
—
0
0
21
219
0.96
0.03
1.3
1.2
—
—
—
0
0
30
292
1.03
0.02
1.4
1.4
—
—
—
0
0
14
147
0.95
0.01
1.0
1.1
—
—
—
0
0
34
337
1.01
0.00
1.4
1.4
—
—
—
0
0
6
59
1.02
0.00
1.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
8
83
0.96
0.00
1.9
1.4
—
—
—
0
0
9
90
1.00
0.00
2.2
1.5
—
—
—
0
0
6
59
1.02
0.00
1.7
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
8
82
0.98
0.00
1.9
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
9
89
1.01
0.00
1.0
1.1
—
—
—
0
0
5
58
0.86
0.00
1.2
1.3
1.3
1.4
nmol/l
—
5
50
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
7
79
0.89
0.00
1.1
1.2
20.4
12.8
u/l
—
7
67
8
82
0.98
0.00
1.9
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
8
84
0.95
0.00
1.9
1.4
—
—
—
0
0
8
84
0.95
0.00
1.9
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_BINOCUMOVOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_BINOCUMOVOTH | 1.212 [1.03, 1.43] | 0.023 |
| Birth year | 0.996 [0.99, 1.0] | 0.359 |
During the follow-up period (1.1.1998 — 31.12.2019), 225 out of 3488 females with H7_BINOCUMOVOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_BINOCUMOVOTH | 1.596 [1.34, 1.91] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 292 out of 2306 males with H7_BINOCUMOVOTH died.
Mortality risk
Mortality risk for people of age
years, who have H7_BINOCUMOVOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.129% | 0.356% |
| 5 | 0.853% | 1.789% |
| 10 | 1.879% | 4.371% |
| 15 | 3.71% | 8.414% |
| 20 | 6.334% | 13.823% |
Relationships between endpoints
↥Index endpoint: H7_BINOCUMOVOTH – Other disorders of binocular movement
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data